Citizens Jmp Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $176.00

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target hoisted by Citizens Jmp from $167.00 to $176.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would suggest a potential upside of 81.14% from the company’s current price.

A number of other analysts have also recently commented on the company. TD Cowen reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. Oppenheimer cut shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. Wells Fargo & Company raised their price target on Rhythm Pharmaceuticals from $129.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Canaccord Genuity Group boosted their target price on shares of Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Finally, Needham & Company LLC reduced their price objective on Rhythm Pharmaceuticals from $148.00 to $139.00 and set a “buy” rating for the company in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $134.36.

Rhythm Pharmaceuticals Price Performance

Shares of NASDAQ RYTM opened at $97.17 on Friday. The stock’s 50-day moving average is $104.28 and its two-hundred day moving average is $103.50. Rhythm Pharmaceuticals has a 1-year low of $45.90 and a 1-year high of $122.20. The company has a market cap of $6.48 billion, a price-to-earnings ratio of -31.34 and a beta of 2.00.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. The company had revenue of $57.25 million for the quarter, compared to analysts’ expectations of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%.Rhythm Pharmaceuticals’s quarterly revenue was up 36.9% on a year-over-year basis. During the same period last year, the firm earned ($0.72) earnings per share. Equities research analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insider Transactions at Rhythm Pharmaceuticals

In other news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the sale, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Pamela J. Cramer sold 3,350 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $111.00, for a total value of $371,850.00. Following the sale, the insider owned 20,814 shares of the company’s stock, valued at $2,310,354. This represents a 13.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 25,003 shares of company stock worth $2,589,015. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

A number of hedge funds have recently bought and sold shares of RYTM. EverSource Wealth Advisors LLC raised its stake in Rhythm Pharmaceuticals by 303.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after buying an additional 200 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after acquiring an additional 141 shares during the last quarter. SBI Securities Co. Ltd. raised its position in shares of Rhythm Pharmaceuticals by 73.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after acquiring an additional 145 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after purchasing an additional 322 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Rhythm Pharmaceuticals by 48.6% in the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock worth $39,000 after purchasing an additional 118 shares during the period.

Key Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — fourth-quarter product revenue of $57.3M (IMCIVREE), revenue up ~36.9% y/y, and EPS loss of ($0.73) that beat consensus. The print and accompanying slide deck reinforce commercial traction. Earnings & Business Update
• Positive Sentiment: Near-term catalysts could boost valuation if positive — PDUFA goal date for the sNDA in acquired HO on March 20, 2026, plus planned topline readouts in March from a 12‑patient Japanese Phase 3 cohort and the EMANATE Phase 3 trial; positive Phase 2 extension data were also highlighted. Business Update & Catalysts
• Positive Sentiment: Guggenheim raised its price target to $143 and maintained a Buy rating, implying a sizable upside from current levels — a bullish analyst signal for investors focused on upside potential. Guggenheim PT Raise
• Neutral Sentiment: Needham cut its price target to $139 but kept a Buy rating — still constructive but a smaller upside than prior. Needham PT Change
• Negative Sentiment: Rhythm forecasts materially higher 2026 non‑GAAP operating expenses of $385M–$415M to support HO launch preparations, which will pressure near‑term profitability and cash burn expectations. Expense Guidance
• Negative Sentiment: Company remains unprofitable with negative net margin and very negative ROE, underscoring execution and margin risk until new indications or scale materially improve results. Earnings Details

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.